Supadopa TR 95-MG Capsule
Made in:
Brand:
Capacity:
Indications Supadopa TR capsule is indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Pharmacology […]
Indications
Carbidopa: When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain.
Dosage & Administration
Converting from Immediate-Release Carbidopa-Levodopa to RYTARY: The dosages of other carbidopa and levodopa products are not interchangeable on a 1:1 basis with the dosages of RYTARY. To convert patients from immediate-release carbidopa-levodopa to RYTARY, first calculate the patient’s current total daily dose of levodopa. The starting total daily dose of RYTARY is as recommended in below mentioned chart. After conversion, any combination of the four RYTARY dosage strengths can be used to achieve an optimal dosing. Adjust the dose and dosing frequency as necessary to maintain patient tolerance and sufficient symptomatic control. Administration of concomitant Parkinson’s disease medications should remain stable while adjusting the RYTARY dose. In clinical trials, RYTARY was administered in divided doses of three to five times a day. The maximum recommended total daily dose of RYTARY is 612.5 mg / 2,450 mg. For patients currently treated with carbidopa and levodopa plus a catechol-O-methyl transferase (COMT) inhibitor (such as entacapone), the initial total daily dose of levodopa in RYTARY described in Table 1 may need to be increased. Use of RYTARY in combination with other levodopa products has not been studied.
Conversion from Immediate Release Carbidopa-Levodopa to RYTARY-
| Total daily dose of Levodopa in immediate release Levodopa-carbidopa | Total daily dose of Levodopa in Levodopa-Carbidopa | Levodopa-Carbidopa dosing regimen |
| 400 mg to 549 mg | 855 mg | 3 capsules RYTARY 95 mg taken TID |
| 550 mg to 749 mg | 1140 mg | 4 capsules RYTARY 95 mg taken TID |
| 750 mg to 949 mg | 1305 mg | 3 capsules RYTARY 145 mg taken TID |
| 950 mg to 1249 mg | 1755 mg | 3 capsules RYTARY 195 mg taken TID |
| Equal to or greater than 1250 mg | 2340 mg or 2205 mg | 3 capsules RYTARY 245 mg taken TID |
Interaction
Contraindications
Side Effects
Advanced Parkinson’s disease: Most common adverse reactions (incidence ≥5% and greater than oral immediate-release carbidopa-levodopa) are nausea and headache.
Pregnancy & Lactation
Lactation: Levodopa has been detected in human milk after administration of carbidopa-levodopa. There are no data on the presence of carbidopa in human milk, the effects of levodopa or carbidopa on the breastfed infant, or the effects on milk production. However, inhibition of lactation may occur because levodopa decreases secretion of prolactin in humans. Carbidopa is excreted in rat milk.
Precautions & Warnings
Use in Special Populations
Therapeutic Class
Storage Conditions
| Capacity | 6 Tablets ( 1 Strips ) |
|---|








Reviews
There are no reviews yet.